Hosted on MSN15m
Amgen Earnings Transcript (NASDAQ:AMGN)
Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...
Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...